Evidence map›Paper›PMID 42368587›Full record

ReviewActa pharmaceutica Sinica. B2026

Engineered extracellular vesicles for combinatorial cancer therapy and imaging.

Anita S La'ah, Nashmin Fayazi Hosseini, Choongmo Kang, Amirhossein Ahmadieh-Yazdi, Mohsen Sheykhhasan, Piao Yang, Armita Ghotaslou, Hamed Manoochehri, Yun Suk Huh, Heemin Kang and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anita S La'ahTaiwan International Graduate Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei 115, China.
Nashmin Fayazi HosseiniResearch Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan 6517838736, Iran.
Choongmo KangDepartment of Materials Science and Engineering, Korea University, Seoul 02841, Republic of Korea.
Amirhossein Ahmadieh-YazdiStem Cell Biology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd 8916978477, Iran.
Mohsen SheykhhasanCellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran.
Piao YangDepartment of Molecular Genetics, College of Arts and Sciences, The Ohio State University, Columbus, OH 43210, USA.
Armita GhotaslouDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz 51385-1444, Iran.
Hamed ManoochehriThe Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr 7514633196, Iran.
Yun Suk HuhNanoBio High-Tech Materials Research Center, Department of Biological Sciences and Bioengineering, Inha University, Incheon 22212, Republic of Korea.
Heemin KangDepartment of Materials Science and Engineering, Korea University, Seoul 02841, Republic of Korea.
Pooyan MakvandiThe Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, 324000 Quzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer treatment has advanced significantly over the past few decades, resulting in improved patient survival outcomes. However, challenges like drug resistance, off-target effects, and systemic toxicity continue to persist. These underscore the importance of modified extracellular vesicles (EVs) as a versatile and innovative platform for delivering combination therapies for cancer. This review highlights the utilization of biocompatible engineered EVs to inhibit cancer progression with reduced side effects. Further, outlining the promising approach to cancer treatment through combination therapies and imaging-guided strategies. Additionally, this review explored the biogenesis and various sources of EVs, which provides clear insights into future directions.

Indexed as

Cancer diagnosisCancer therapyCombination therapyDrug deliveryGene therapyImaging-guided therapyImmunotherapyModified extracellular vesicles

Identifiers

PMID42368587
PMCPMC13304764

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.